ArticlePharmacoEconomics2021

Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.

Daniel Stellato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.